Multiple sclerosis epidemiology in Middle East and North Africa: A systematic review and meta-analysis by Heydarpour, P. et al.
E-Mail karger@karger.com
 Systematic Review 
 Neuroepidemiology 2015;44:232–244 
 DOI: 10.1159/000431042 
 Multiple Sclerosis Epidemiology in Middle 
East and North Africa: A Systematic Review 
and Meta-Analysis 
 Pouria Heydarpour  a    Shayan Khoshkish  a    Shabnam Abtahi  a    Maziar Moradi-Lakeh  b  
Mohammad Ali Sahraian  a   
 a   MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, and  b   Department of Community 
Medicine, Iran University of Medical Sciences,  Tehran , Iran
 
MS prevalence ranged from 14.77/100,000 population in 
 Kuwait (2000) to 101.4/100,000 in Turkey (2006). The overall 
MS prevalence in the region was 51.52/100,000. The mean 
age at disease onset ranged from 25.2 years in Kuwait to 32.5 
years in Northeastern Iran, with an overall estimate of 28.54 
years.  Conclusions: Recent advances in MS registries will al-
low nation-wide studies and temporal comparisons be-
tween countries, provided that age- and sex-standardized 
estimates are available.  © 2015 S. Karger AG, Basel 
 Background 
 Multiple sclerosis (MS) is an inflammatory demyelinat-
ing and neurodegenerative disease affecting more than 
2 million people worldwide  [1] . MS may have a variable 
clinical course; episodic acute periods of relapses, gradual 
progressive decline of neurologic function, or combina-
tions of both  [2] . MS typically begins in early adulthood; 
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 Abstract 
 Background: Multiple sclerosis (MS) is one of the most com-
mon neurological disorders and a leading cause of nontrau-
matic disability in young adults in many countries. Recent 
reports from the Middle East and North Africa have suggest-
ed a moderate to high risk of MS in these countries.  Meth-
ods: A literature search was performed in August 2014 in 
MEDLINE, EMBASE, and IMEMR to retrieve original popula-
tion-based studies on MS epidemiology in the Middle East 
and North African countries published between 1st January 
1985 and 1st August 2014. We designed search strategies 
using the key words: MS, prevalence, incidence, and epide-
miology. According to the inclusion criteria, 52 studies were 
included in this systematic review.  Results: McDonald’s cri-
teria were the most widely used diagnostic criteria in the 
studies. Most studies were conducted in single hospital-
based centers with a defined catchment area. The female/
male ratio ranged from 0.8 in Oman to 4.3 in Saudi Arabia. 
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15 years after the onset of disease, up to 50 percent of pa-
tients will need help in walking  [3] . An almost universal 
increase in prevalence and incidence of MS over time with 
a general increase in the incidence of MS in females has 
been observed in meta-analyses of studies on MS epidemi-
ology since 1965  [4] . A longitudinal study in Canada over 
the past 50 years suggests that different smoking habits 
could explain the increase in the female/male sex ratio  [5] .
 Middle Eastern and North African countries are lo-
cated in a low- to moderate-risk zone for MS based on the 
2013 MS Atlas  [6] ; however, recent studies suggest a mod-
erate-to-high prevalence in areas within this region, with 
an increase in the incidence and prevalence especially 
among women  [7–11] . Increasing burden of MS in Mid-
dle Eastern countries, in addition to high costs of manag-
ing this condition, denotes a special notice to reliable ep-
idemiological data for healthcare planning and policy-
making purposes.
 Disparities in environmental risk factors and genetic 
predispositions modulate the risk of MS at the popula-
tion level  [12] . Studying changes in the incidence and 
prevalence could reveal temporal and spatial patterns 
contributing to variable MS risk across populations. Giv-
en the limited epidemiological data on MS in Middle East 
and North African countries, this systematic review aims 
to pool all available data to elucidate trends in the inci-
dence, prevalence, and natural history of MS in these 
countries.
 Materials and Methods 
 Screening and Eligibility Criteria 
 The following criteria were used to select papers for inclusion 
in this systematic review: (1) the population defined primarily as 
those living in Middle Eastern/North African countries; our defini-
tion of the Middle East and North African countries was based on 
the global burden of diseases definition of North Africa and the 
Middle East region, including the following 21 countries: Algeria, 
Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, 
 Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, 
 Tunisia, Turkey, United Arab Emirates, Western Sahara, and 
 Yemen  [13] . (2) MS was defined according to accepted interna-
tional diagnostic criteria in use at the time of the study (Poser et al. 
 [14] or McDonald’s criteria)  [15–17]. (3) The prevalence, inci-
dence, or number of MS cases were reported in the study. (4) Ar-
ticles in English language were included in this study. We excluded 
articles primarily focusing on other fields of MS: neuroimaging, 
neuroimmunology, and not providing estimates on MS prevalence. 
Studies before 1985, when magnetic resonance imaging (MRI) be-
came a part of clinical practice and substantially influenced the di-
agnosis of MS, were few in this region and we have incorporated 
this exclusion criteria similar to other systematic reviews on MS 
epidemiology in other regions  [18–20] . We did not include Israel 
in our study because WHO considered it as a high-income  European 
country; thus, it is beyond the scope of this review  [21, 22] .
 The flow diagram of study selection was developed according 
to PRISMA statement ( fig. 1 ).
 Search Strategy 
 We have queried the MEDLINE, EMBASE, and IMEMR with 
the following keywords: ‘MS’, ‘incidence’, ‘prevalence’, and ‘epide-
miology’. Our search strategy is provided in the online supplemen-
175 records identified through EMBASE
105 records identified through MEDLINE
8 additional records identified
through IMEMR
233 records after duplicate removal
109 records were screened
67 full-text articles assessed
for eligibility
52 studies included
42 records excluded
15 full-text articles excluded
3 review articles
9 not prevalence or incidence study
3 editorials or letters
Inc
lus
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Elig
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lity
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n
124 articles were found to have
irrelevant titles
 Fig. 1. Flow diagram of studies based on the 
PRISMA statement. 
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tary files (for all online suppl. material, see www.karger.com/
doi/10.1159/000431042). We also did a manual search of reference 
lists from primary articles and relevant reviews. 
 Quality Assessment and Data Extraction 
 Two independent reviewers (P.H. and S.K.) used the Joanna 
Briggs Institute critical appraisal tools to assess the methodological 
quality of each study  [23] . If the two reviewers disagreed on the 
final critical appraisal and this could not be resolved through dis-
cussion, a third reviewer’s opinion was sought (S.A.). Quality 
scores of the studies are presented in detail in online supplemen-
tary table 1. A trained reviewer extracted following data into a stan-
dardized form: the study period, location, diagnostic criteria, 
number of cases, female/male ratio, average age of the study popu-
lation, mean age at disease onset, and MS subtype proportions. 
Crude and standardized prevalence and incidence estimates were 
documented overall and by sex, region, time period, and subgroup 
as applicable.
 Statistical Analysis 
 Meta-analysis was performed for pooled data for prevalence, 
mean age at disease onset, female proportion of patients, and MS 
subtype proportions using STATA software version 13 (Stata 
Corp., College Station, Tex., USA). A moment-based random 
model was used for estimating pooled measures because of hetero-
geneity of studies. We used metaregression to find trend of chang-
es in the above-mentioned variables over time.
 Results 
 Our literature review resulted in 233 studies after du-
plicate removals. Among these studies, 124 studies had 
irrelevant titles and 42 studies did not pass the eligibility 
criteria during the abstract/full-text screening. Finally, we 
included 52 studies in this systematic review ( fig. 1 ).  Ta-
ble 1 shows the study period, type, location, diagnostic 
criteria, number of cases, female/male ratio, mean age at 
disease onset, prevalence rates, incidence rates, and qual-
ity scores in these studies.
 Our search on epidemiology of MS in Middle East and 
North African countries yielded no results in Bahrain, 
Morocco, Palestine, Syria, Western Sahara, and Yemen. 
Single hospital-based studies covering mainly capital cit-
ies were the only source of information on MS epidemiol-
ogy in UAE, Saudi Arabia, Qatar, Oman, Lebanon, Iraq, 
and Algeria. We have presented these studies separately 
in  table 2 . Detailed quality scores of studies included in 
this systematic review are presented in online supple-
mentary tables 1 and 2.
 McDonald’s criteria were the most widely used diag-
nostic criteria (44%), Poser et al. criteria were used in 36% 
of studies. The 2005 revision of McDonald’s criteria was 
used in 14%, while the 2010 revision was only used in two 
studies and Schumacher and McAlpine criteria were used 
in one study.
 Community-based surveys were conducted in 7% of 
the studies to estimate the prevalence of MS  [24–27] . Re-
gional MS registries were used as the data source to obtain 
patient records in 30% of studies  [7–9, 28–40] , while sin-
gle hospital-based studies accounted for 34% of studies 
 [10, 41–57] and 23% of studies were conducted in a mul-
ticenter hospital-based setting  [11, 58–68] . One study 
used the ministry of health data for interferon therapy as 
the data source  [69] .
 The female/male sex ratio varied among studies in the 
region, ranging from 0.8 in Oman  [50] to 4.3 in Saudi Arabia 
 [54] . The overall pooled estimate of female proportion of 
MS patients was 0.67 (0.65–0.69) and this proportion 
 slightly increased over time (Coef. 0.004, p = 0.03;  fig. 2 ).
 Study methodologies and the quality of the methods 
can influence the estimates of prevalence rates in epide-
miological studies;  figure 3 depicts the heterogeneity of 
prevalence rates (with confidence intervals) in this re-
gion. Prevalence rates range from 14.77/100,000 in 
 Kuwait (2005  [46] ) to 101.4/100,000 in Turkey (2006 
 [27] ). Meta-analysis of the pooled estimates are presented 
in  table 3 , an overall prevalence of 51.52/100,000 (36.10–
66.95/100,000) was estimated for countries in this region 
(heterogeneity statistic = 4,835.85, I 2 = 99.8%). A metare-
gression analysis showed a significant increase in MS 
prevalence in this region over time (Coef. 2.89, p = 0.03).
 The annual MS incidence rate in the Middle East and 
North African countries was only reported in few studies 
ranging from 0.8 in Libya (1985  [65] ) to 9.1/100,000 in 
 Isfahan (2011  [7] ). The 3-year incidence rate in Isfahan was 
reported to be 26.03/100,000 in a later study (2013  [9] ).
 The mean age at disease onset was similar in these 
countries, ranging from 25.2 in Kuwait  [64] to 32.5 in 
Northeastern Iran  [38] .  Figure 4 demonstrates studies re-
porting the mean age at disease onset. Meta-analysis re-
vealed an overall mean age at the onset of 28.54 years for 
MS patients (27.61–29.48); the age at disease onset did 
not change significantly over time (Coef. 0.09, p = 0.23).
 Several studies reported the following course of dis-
ease in patients: relapsing-remitting MS (RRMS), sec-
ondary-progressive MS (SPMS), primary-progressive MS 
(PPMS), and relapsing-progressive MS (RPMS). The 
overall proportions of these MS subtypes are presented in 
 table 4 . We only found a slight decrease in PPMS in the 
region over time (Coef. –0.006, p = 0.01).
 Age- and sex-specific prevalence rates were reported in 
few studies; as these measures provide the most useful es-
timates to compare MS among countries, we have pro-
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2008
2013
2009
2011
2009
2011
2010
2011
2009
2011
2009
2007
2007
2005
1993
2013
1988
1984
2008
2012
2009
2006
2003
2004
2009
2010
2009
2008
2002
2000
2010
2000
2007
2006
2000
2010
2010
2007
1995
1986
2007
3.20
3.45
3.46
2.34
3.23
3.32
2.37
3.34
3.23
3.24
3.32
3.21
1.85
2.86
2.45
3.32
2.68
0.93
1.48
3.12
0.39
1.27
1.26
1.53
2.94
3.10
1.99
1.99
2.90
1.43
2.87
2.96
2.72
1.52
1.15
2.51
2.48
2.56
2.08
1.04
2.92
100.00
Egypt
Iran
Iran
Iran
Iran
Iran
Iran
Iran
Iran
Iran
Iran
Iran
Jordan
Jordan
Jordan
Kuwait
Kuwait
Libya
Sudan
Tunisia
Turkey
Turkey
Turkey
Turkey
Algeria
Iraq
Iraq
Iraq
Iraq
Jordan
Kuwait
Kuwait
Lebanon
Lebanon
Oman
Qatar
Qatar
Saudi Arabia
Saudi Arabia
Saudi Arabia
UAE
Hashem [58]
Etemadifar [9]
Elhami [29]
Jajvandian [40]
Ghandehari [32]
Ebrahimi [33]
Moghaddam [72]
Majdinasab [35]
Sharafaddinzadeh [36]
Rezaali [37]
Hashemilar [38]
Abedini [39]
Al-Shimmery [60]
El-Salem [61]
Al-Din [62]
Alroughani [11]
Al-Din [64]
Radharkrishan [65]
Idris [66]
Sidhom [67]
Recep [25]
Turk Boru [27]
Boru [26]
Celik [68]
Hecham [41]
Hasan [42]
Hasan [57]
Al-Hamadani [43]
Al-Araji [44]
Bahou [45]
Alroughani [56]
Alshubaili [46]
Yamout [47]
Sawaya [48]
Tharakan [50]
Deleu [10]
Akhtar [51]
Al Deeb [52]
Daif [53]
Yaqub [54]
Inshasi [55]
Overall (I2 = 91.3%, p = 0.000)
Note: weights are from random effects analysis
First
author Country Year
%
Weight
0.3 0.4 0.6 0.8 0.9
 Fig. 2. Female proportion of MS patients in studies from Middle East and North Africa. 
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vided them in online supplementary table 3. We have also 
presented the annual number of cases (incidence data) by 
the calendar year of onset in online supplementary table 4.
 A brief description of the epidemiology and natural 
history of MS in each country is presented here:
 Algeria 
 MS has been scarcely documented in Algeria, 307 pa-
tients were reported to have MS in a single hospital-based 
study. Most patients experienced motor symptoms as the 
presenting symptom (73.6%); RRMS was reported in 
61.9%, secondary progressive in 19.5%, and progressive 
in 18.6% patients  [41] .
 Egypt 
 A community-based survey in Al Quseir, Egypt, has 
found an MS prevalence of 13.74/100,000  [24] . A retro-
spective meta-analysis in different referral centers of 
Egypt has found 648 patients with definite MS. The most 
frequent presenting symptom was weakness (57%), fol-
Table 3.  Meta-analysis of the pooled estimates for prevalence, mean age at disease onset, and female proportion of patients
Overall estimate Pooled estimate Lower limit Upper limit Heterogeneity 
statistic
Degrees of freedom p value I2, %
Prevalence 51.52 36.10 66.95 4,835.85 11 0.000 99.8
Mean age at onset 28.54 27.61 29.48 487.96 15 0.000 96.9
Female proportion 0.67 0.65 0.69 459.38 40 0.000 91.3
2013
2009
2007
2005
1993
2013
2006
2003
2004
2000
2010
2007
Iran
Iran
Iran
Jordan
Jordan
Kuwait
Turkey
Turkey
Turkey
Kuwait
Qatar
UAE
8.77
8.78
8.78
8.66
7.86
8.77
7.64
5.91
8.77
8.78
8.67
8.60
100.00
85.80 (83.25, 88.35)
50.57 (49.46, 51.68)
20.10 (18.40, 21.80)
39.00 (32.80, 45.20)
32.10 (14.25, 49.95)
85.05 (82.93, 87.17)
50.60 (30.47, 70.73)
101.40 (65.09, 137.71)
33.90 (31.90, 35.90)
14.77 (13.19, 16.35)
64.57 (58.54, 70.60)
54.77 (46.99, 62.55)
51.53 (36.11, 66.95)
Etemadifar [9]
Elhami [29]
Abedini [39]
El-Salem [61]
Al-Din [62]
Alroughani [11]
Turk Boru [27]
Boru [26]
Celik [68]
Alshubali [46]
Deleu [10]
Inshasi [55]
Overall (I2 = 99.8%, p = 0.000)
First
author
%
WeightCountry Year ES (95% CI)
0 20 40 60 80 100 120
Note: weights are from random effects analysis
 Fig. 3. Prevalence of of MS in studies from Middle East and North Africa. 
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lowed by sensory symptoms (19.9%), visual symptoms 
(15.9%), and ataxia (15.8%). 73.45% of these patients had 
a relapsing-remitting course, primary-progressive course 
was seen in 17% of patients, and 9.55% had the second-
ary-progressive course.
 Iran 
 The MS prevalence in Tehran has increased from 
51.9/100,000 in 2008 to 74.28/100,000 in 2011. The an-
nual MS incidence has significantly increased over the 
last two decades from 0.68 (1989) to the peak of 5.68/ 
100,000 (2005). The disease was almost 3 times more 
common in females than in males. RRMS was recognized 
in 84.9% of patients. The mean age at disease onset was 
27.24 years; there was a positive family history of MS in 
9.5% of the patients  [8, 29, 30] .
 Population-based studies in Isfahan have revealed a 
general increase in MS prevalence and incidence over a 
decade, the MS prevalence has increased from 35.5 in 
2006 to 85.8 per 100,000 in 2013, with an incidence of 9.1 
Table 4.  Meta-analysis of MS subtype proportion estimates
MS subtype proportions Pooled estimate Lower limit Upper limit Heterogeneity statistic Degrees of freedom p value I2, %
RRMS 0.74 0.71 0.77 578.27 32 0.000 94.5
SPMS 0.12 0.10 0.15 1,250.50 30 0.000 97.6
PPMS 0.08 0.06 0.11 1,097.72 28 0.000 97.4
RPMS 0.06 0.02 0.10 97.00 29 0.000 70.1
2009
2010
2009
2007
2005
1993
1988
2003
2004
2010
2002
2010
2000
2007
2010
1995
7.06
7.03
6.93
6.83
6.27
6.12
6.44
4.13
4.49
6.82
6.66
6.43
6.71
6.10
6.16
5.83
100.00
27.53 (27.35, 27.71)
28.20 (27.90, 28.50)
32.50 (31.99, 33.01)
26.90 (26.23, 27.57)
29.30 (28.04, 30.56)
29.60 (28.21, 30.99)
25.20 (24.10, 26.30)
31.70 (28.73, 34.67)
29.20 (26.53, 31.87)
30.92 (30.24, 31.60)
29.20 (28.32, 30.08)
26.80 (25.69, 27.91)
26.00 (25.18, 26.82)
30.20 (28.79, 31.61)
27.00 (25.64, 28.36)
27.70 (26.08, 29.32)
28.55 (27.61, 29.48)
Iran
Iran
Iran
Iran
Jordan
Jordan
Kuwait
Turkey
Turkey
Iraq
Iraq
Kuwait
Kuwait
Lebanon
Qatar
Saudi Arabia
Elhami [29]
Etemadifar [7]
Hashemilar [38]
Abedini [39]
El-Salem [61]
Al-Din [62]
Al-Din [64]
Boru [26]
Celik [68]
Hasan [42]
Al-Araji [44]
Alroughani [56]
Alshubaili [46]
Yamout [47]
Deleu [10]
Daif [53]
Overall (I2 = 96.9%, p = 0.000)
Note: weights are from random effects analysis
20 25 30 35 40
Country Year ES (95% CI)
%
Weight
First
author
 Fig. 4. The mean age at MS onset of studies in Middle East and North Africa. 
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in 2009. Similar to Tehran, a female to male ratio of 3.37 
was seen with a family history of MS in 12.2% of patients. 
The clinical course of MS was RRMS in 87.8%, SPMS in 
6.4%, and PPMS in 5.7% of patients. The initial presenta-
tion was sensory in 51.7%, and visual disturbances were 
seen in 47.5% of patients. Early and late onset MS was 
seen in 5 and 1.1% of patients, respectively, and the mean 
age at disease onset was 28.2 years  [7, 9, 28, 31, 70] .
 Variable prevalence rates have been reported from 
 other regions in Iran, prevalence rate was 20.1 per 100,000 
in Mazandaran (North Iran)  [39] , 27.7 in East Azerbaijan 
(Northwest Iran)  [38] , 16.28 in Khuzestan (Southwest 
Iran)  [36] , 13.96 in Sistan and Balouchestan (Southeast 
Iran)  [71], and ranging from 5.3 to 12.9 in Khorasan 
(Northeast Iran)  [32] . A higher prevalence of MS was seen 
in central provinces of Qom (50.4) and Kerman (31.5), 
similar to reports from Tehran and Isfahan  [33, 37] .
 Iraq 
 A progressive increase in MS prevalence and a trend 
toward more female patients was observed in Iraq in the 
last two decades. The initial symptom was reported as 
motor in 31.7%, sensory in 28.3%, optic nerve in 24% and 
brainstem or cerebellar in 22.3% of patients. The course 
was relapsing remitting in 66.3% patients, secondary pro-
gressive in 18.7%, and primary progressive in 15% pa-
tients. However, a different medical care pattern among 
the male and female patients in Iraq resulted in a lower 
female to male gender ratio (1.2: 1) compared to the west-
ern nations  [44] . In another study, the mean age at clini-
cally definite MS onset was 30.92  [42]; Hasan et al. showed 
that 6.8% of their patients attending an MS clinic in Iraq 
experienced MS symptoms before the age of 18 years  [57] .
 Jordan 
 Jordan has been considered as an area of low to me-
dium risk of MS, a 2-year hospital-based study on 126 MS 
patients (1992–1993) reported a prevalence of 42/100,000 
among patients with Palestinian origin, while the preva-
lence among patients with Jordanian origin was 20  [62, 
63] . However, a more recent study reported a prevalence 
rate of 39/100,000 in the city of Amman and 38 in Irbid, 
regardless of the origin of the ancestors. Fifty-seven new 
cases were diagnosed in the study year, resulting in an 
incidence of 1.14/100,000. The mean age of onset was 
29.3 years. The most common clinical presentation was 
weakness (30.8%), followed by optic neuritis (20.1%), 
sensory impairment (19.6%), and ataxia (14.3%). A pos-
itive family history of MS was found in 9.4% of the cases 
 [61] .
 Kuwait 
 Alshubaili et al. reported that the MS incidence rate 
has increased from 1.05 in 1993 to 2.62/100,000 in 2000. 
An increasing pattern was also observed in the prevalence 
rates (6.68/100,000 at the end of 1993 to 14.77/100,000 by 
2000). The estimated prevalence was markedly higher for 
Kuwaitis (31.15) than for non-Kuwaitis (5.55)  [46] . Na-
jim Al-Din et al. found a statistically different prevalence 
rate among Kuwaitis (9.5) and Palestinians (23.8) resi-
dent in Kuwait. The most common symptom at diagnosis 
were sensory (52.4%) and motor weakness (50.0%), fol-
lowed by unilateral optic neuritis (32.5%), ocular palsy 
(25.7%), and cerebellar signs (24.6%)  [64] . A more recent 
study reported an 85.05/100,000 crude prevalence rate of 
MS in Kuwait in 2011, with a higher prevalence in wom-
en  [11] .
 Lebanon 
 Based on the Lebanese ministry of health records, to-
tal number of MS patients is estimated to be between 
1,200 and 1,700. The most frequent presenting symp-
toms were brainstem-cerebellar (46.2%), followed by 
sensory (42.5%), motor (33.9%), and visual (29.6%). 
RRMS was seen in 85.1% of patients at onset, and 7.9% 
had PPMS. The female patients outnumbered males 
with a female to male ratio of 1.8: 1. The mean age at on-
set of disease was 30.2 years. A positive family history of 
MS was reported by 5% of patients; however, Sawaya 
and Kanso found 30% of their group of patients had a 
first- or second-degree relative diagnosed with MS  [47, 
48] .
 Libya 
 The sole study on MS epidemiology in Libya dates 
back to 1985, where MS cases were detected yielding a 
crude prevalence rate of 4 per 100,000 and the age-adjust-
ed prevalence rate of 5.9/100,000. A high prevalence of 
brainstem involvement and cerebellar dysfunction was 
seen in this study  [65] .
 Oman 
 Oman has the lowest reported MS occurrence in the 
Arabian Peninsula; however, the MS prevalence has in-
creased from 1.2/100,000 in 1996 to 4/100,000 in 2000. 
Among 30 patients with MS diagnosis, 23 patients had 
the relapsing-remitting course, 4 were secondary pro-
gressive, and 3 were primary progressive. Twelve pa-
tients presented with blurred vision, 6 with sensory 
symptoms, 5 with ataxia, 3 with diplopia, and 2 with 
hemiplegia  [49] .
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 Qatar 
 MS in Qatar is an emerging neurologic disorder; in the 
first epidemiological study of MS in Qatar, the crude 
prevalence was reported 64.57/100,000 (2010). The fe-
male/ male ratio (1.33: 1) was remarkably lower than that 
observed in the remaining countries of the region. A pos-
itive family history was found in 10.4% of patients. The 
most common symptom at presentation was sensory 
manifestations, followed by optic neuritis or pyramidal 
symptoms  [10] . In another study, 58.5% patients had the 
RRMS disease course, 4.5% had SP, 2% had PP, and 7% 
had CIS.
 Saudi Arabia 
 MS prevalence is low in Saudi Arabia (25/100,000) 
 [54]. The clinical course was relapsing remitting in 60.7%, 
progressive relapsing in 20.2%, and primary progressive 
in 19.1%. The mean age at onset in Saudi patients (25.9 
years) was lower than that of the non-Saudis (29.4 years). 
In the Saudi and non-Saudi group, the female/male ratio 
was 1.32: 1 and 1.4: 1, respectively. Weakness was the 
most common presenting symptom in both the Saudi 
and non-Saudi patients, followed by sensory impairment 
 [53] .
 Sudan 
 Only 35 patients were seen during one decade in a cen-
tral-tertiary specialized neurology center in Sudan. The 
most common presentation was paralysis of one or more 
extremities (68.6%), followed by optic neuritis (37.1%), 
cerebellar ataxia (11.4%), and diplopia (5.7%). The re-
lapsing-remitting course was seen in 56% of patients, sec-
ondary progressive in 32%, and 9% had the primary-pro-
gressive course  [66] .
 Tunisia 
 In a multicenter hospital-based study conducted in 
Tunisia, 437 MS patients were included. Their disease 
course was relapsing remitting in 91% of patients and pri-
mary progressive in 9%. The most frequent symptoms at 
onset were motor (28%), optic neuritis (20%), and sen-
sory (16%) dysfunction  [67] .
 Turkey 
 MS prevalence in urban Istanbul (101.3/100,000) was 
nearly more than twice the prevalence in rural regions 
of  Northern Turkey: Kandıra (61/100,000), Geyve (41/ 
100,000), Erbaa (53/100,000), and Caucasus (68.97/ 
100,000)  [25–27] . The previous MS prevalence rate from 
Edrine city was reported to be 33.9/100,000 in 2003  [68] . 
Türk Börü et al. reported that the initial symptoms in 
51.5% of subjects were sensory, brainstem-related signs 
(42%), cerebellar signs (33%), motor signs (30%), optic 
neuritis (30%), and sphincter disturbances (15%)  [27] .
 United Arab Emirates 
 The crude prevalence rate of MS in Dubai was 19.2 per 
100,000 in the whole population, while in the Dubai na-
tive population was 54.77. The annual incidence rate was 
6.8/100,000 during 2000–2007. Majority of Dubai native 
patients had the RRMS disease course (76.9%), 10.6% 
were SP, 7.8% were CIS, and 4.4% were RP. The mean age 
of onset was 26.6 years and the female/male ratio was 
2.85: 1. The most common symptom at presentation was 
motor (72.78%), followed by sensory (48.41%), cerebellar 
(19.96%), and ocular (16.13%)  [55] .
 Discussion 
 Our systematic review yielded 52 studies on epidemi-
ology of MS in the Middle East countries. Main findings 
are: (1) McDonald’s criteria were the most widely used 
diagnostic criteria. (2) Most of the studies were conduct-
ed in single hospital-based centers. (3) The female/male 
ratio ranged from 0.8 (Oman) to 4.3 (Saudi Arabia). (4) 
The overall MS prevalence in the region was 51.52/100,000. 
(5) The mean age at disease onset ranged from 25.2 years 
(Kuwait) to 32.5 years (Northeastern Iran), with an over-
all estimate of 28.54 years.
 The geographical distribution of MS patients has been 
the subject of numerous studies worldwide. Recent sys-
tematic reviews on the prevalence of MS in different re-
gions of the world illustrate the changing epidemiology 
of disease and point to genetic and environmental dis-
parities among these communities, leading to a global in-
crease of MS. Reports from regions lacking sufficient ep-
idemiological studies could be of particular importance 
in this regard. In this study, we tried to gather studies 
from the MENA countries.
 Reports on MS prevalence with higher quality scores 
were derived from multicenter studies and regional reg-
istries in the capital or large cities within the country; na-
tionwide studies were rare in the MENA countries. High-
er quality scores of recent publications, and an increased 
prevalence in studies from the same areas over time, bring 
the conclusion of an increasing disease prevalence in the 
region.
 Prevalence rates in our study ranged from 14.77/ 
100,000 in Kuwait (2000) to 101.4/100,000 (Turkey). 
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